knowledge -WSS

knowledge

author：comprehensive 2025-08-12 11:29:23 - browse：7236

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT

WSS

PhRMA sues HHS over Medicare drug price negotiation

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

PhRMA sues HHS over Medicare drug price negotiation

Inside the fall of star MIT scientist David Sabatini

Bacterial infection may be ‘key event’ in endometriosis, study says

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

knowledge

leisure time

Supreme Court strikes down use of affirmative action

FDA does about

Heart attack and stroke risk calculators need revising

Grail is spending more than ever lobbying Congress

Virginia high school admissions case could be legal follow

Why is France rioting? What to know about the fatal police shooting of Nahel M

At least 13 dead in Texas as scorching temps continue

PhRMA sues HHS over Medicare drug price negotiation

Virginia high school admissions case could be legal follow

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

focus

How to fix the rural physician shortage in the U.S.

Change Healthcare cyberattack outage could last weeks

House looks to weaken Medicare negotiation

Australia's humpback populations rebound raising hopes of marine scientists

New case study details death in closely watched Alzhiemer's trial

ALS groups 'won't be played again' by the FDA, drug sponsors

hotspot

hotspot

leisure time

focus